Show simple item record

dc.contributor.authorRodríguez-Martínez, Carlos E.
dc.contributor.authorNiño, Gustavo
dc.contributor.authorCastro-Rodriguez, Jose A.
dc.contributor.authorAcuña-Cordero, Ranniery
dc.contributor.authorSossa-Briceño, Mónica P.
dc.contributor.authorMidulla, Fabio
dc.date.accessioned2021-04-21T13:46:54Z
dc.date.available2021-04-21T13:46:54Z
dc.date.issued2021-01-02
dc.identifier.issn0301-0546,spa
dc.identifier.urihttp://hdl.handle.net/20.500.12495/5801
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherElsevierspa
dc.relation.ispartofseriesAllergologia et immunopathologia, 0301-0546, Vol. 49, Nro. 1, 2021, p. 153-158spa
dc.relation.urihttps://all-imm.com/index.php/aei/article/view/12spa
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleFor which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?spa
dc.type.localArtículo de revista
dc.subject.keywordsBronchiolitisspa
dc.subject.keywordsViral bronchiolitis phenotypingspa
dc.subject.keywordsClinical practice guidelinesspa
dc.subject.keywordsPhenotype-specific treatmentspa
dc.identifier.doihttps://doi.org/10.15586/aei.v49i1.12spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.publisher.journalAllergologia et immunopathologiaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.identifier.instnameinstname:Universidad El Bosque
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.title.translatedFor which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?spa
dc.description.abstractenglishAlthough there is increasing evidence showing that infants with viral bronchiolitis exhibit a high degree of heterogeneity, a core uncertainty shared by many clinicians is with regard to understanding which patients are most likely to benefit from bronchodilators such as albuterol. Based on our review, we concluded that older infants with rhinovirus (RV) bronchiolitis, especially those with a nasopharyngeal microbiome dominated by Haemophilus influenzae; those affected during nonpeak months or during non-respiratory syncytial virus (RSV) predominant months; those with wheezing at presentation; those with clinical characteristics such as atopic dermatitis or a family history of asthma in a first-degree relative; and those infants infected with RSV genotypes ON1 and BA, have the greatest likelihood of benefiting from albuterol. Presently, this patient profile could serve as the basis for rational albuterol administration in patients with viral bronchiolitis, at least on a therapeutic trial basis, and it could also be the starting point for future targeted randomized clinical trials (RCTs) on the use of albuterol among a subset of infants with bronchiolitis.spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abiertospa


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución-NoComercial-CompartirIgual 4.0 Internacional